About: Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020
Creator	Skowronski, Danuta Henry2, Bonnie Krajden3, Mel
Source	MedRxiv
abstract	Background: The province of British Columbia (BC) has been recognized for successful SARS-CoV-2 control, with surveillance data showing amongst the lowest case and death rates in Canada. We estimate sero-prevalence for two periods flanking the start (March) and end (May) of first-wave mitigation measures in BC. Methods: Serial cross-sectional sampling was conducted using anonymized residual sera obtained from an outpatient laboratory network, including children and adults in the Greater Vancouver Area (population ~3 million) where community attack rates were expected to be highest. Screening used two chemiluminescent immuno-assays for spike (S1) and nucleocapsid antibodies. Samples sero-positive on either screening assay were assessed by a third assay targeting the S1 receptor binding domain plus a neutralization assay. Age-standardized sero-prevalence estimates were based on dual-assay positivity. The May sero-prevalence estimate was extrapolated to the source population to assess surveillance under-ascertainment, quantified as the ratio of estimated infections versus reported cases. Results: Serum collection dates spanned March 5-13 and May 15-27, 2020. In March, two of 869 specimens were dual-assay positive, with age-standardized sero-prevalence of 0.28% (95%CI=0.03-0.95). Neither specimen had detectable neutralizing antibodies. In May, four of 885 specimens were dual-assay positive, with age-standardized sero-prevalence of 0.55% (95%CI=0.15-1.37%). All four specimens had detectable neutralizing antibodies. We estimate ~8 times more infections than reported cases. Conclusions: Less than 1% of British Columbians had been infected with SARS-CoV-2 when first-wave mitigation measures were relaxed in May 2020. Our findings indicate successful suppression of community transmission in BC, but also substantial residual susceptibility. Further sero-survey snapshots are planned as the pandemic unfolds.
has issue date	2020-07-15(xsd:dateTime)
bibo:doi	10.1101/2020.07.13.20153148
has license	medrxiv
sha1sum (hex)	e1c77d15fda784cd75d999415196cef58886a901
schema:url	https://doi.org/10.1101/2020.07.13.20153148
resource representing a document's title	Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020
resource representing a document's body	covid:e1c77d15fda784cd75d999415196cef58886a901#body_text
is schema:about of	named entity 'substantial' named entity 'Canada' named entity 'British' named entity 'END' named entity 'START' named entity 'SPRING' named entity 'MEASURES' named entity 'SERA' named entity 'SARS-COV-2' named entity 'British Columbia' named entity 'residual' named entity 'sero' named entity 'asymptomatic' named entity 'SARS-CoV-2' named entity 'Hong Kong' named entity 'nucleocapsid' named entity 'preprint' named entity 'coronaviruses' named entity 'antibody' named entity 'sero' named entity 'preprint' named entity 'sero' named entity 'IgG' named entity 'symptom' named entity 'North America' named entity 'preprint' named entity 'Public Health England' named entity 'care facilities' named entity 'cytopathogenic effect' named entity 'preprint' named entity 'medRxiv' named entity 'SARS-CoV-2' named entity 'severe acute respiratory syndrome coronavirus' named entity 'enzyme immunoassay' named entity 'neutralizing antibodies' named entity 'sero' named entity 'Lower Mainland' named entity 'medRxiv' named entity 'seropositive' named entity 'sero' named entity 'preprint' named entity 'SARS-CoV-2' named entity 'medRxiv' named entity 'outpatient' named entity 'preprint' named entity 'World Health Organization' named entity 'sero' named entity 'Lower Mainland' named entity 'seroprevalence' named entity 'COVID' named entity 'peer review' named entity 'Siemens Healthineers' named entity 'GMT' named entity 'antibody' named entity 'SARS-CoV-2' named entity 'peer review' named entity '85%' named entity 'March 9' named entity 'medRxiv' named entity 'Health Canada' named entity 'Erlangen' named entity 'test sensitivity' named entity 'S/C' named entity 'nucleocapsid' named entity 'preprint' named entity 'medRxiv' named entity 'blood donation' named entity 'peer review' named entity 'IgM' named entity 'nucleocapsid' named entity 'IgG' named entity 'preprint' named entity 'medRxiv' named entity 'asymptomatic infections' named entity 'cumulative incidence' named entity 'Canada' named entity 'avian influenza' named entity 'emerging pathogen' named entity 'serum' named entity 'China' named entity 'A(H1N1)pdm09' named entity 'Emergency Use Authorization' named entity 'neutralizing antibodies'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software